DS
BIOR

David Shaw’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

David Shaw’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,053
Closed -$550K – 6160
2021
Q4 		$550K Buy
+1,053
New +$756K ﹤0.01% 4350
2021
Q3 		– Sell
-968
Closed -$864K – 5437
2021
Q2 		$864K Buy
+968
New +$740K ﹤0.01% 3665
2021
Q1 		– Sell
-177
Closed -$235K – 4608
2020
Q4 		$235K Buy
+177
New +$260K ﹤0.01% 3679

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

David Shaw's BIOR Position: Q1 2022 in Review

David Shaw sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q1 2022, closing a stake of 1,053 shares — an estimated $550K sold.

David Shaw first reported a position in BIOR in Q4 2020 and held it in 3 quarters. The position peaked at $864K in Q2 2021. 51 funds tracked by Wall St. Rank hold BIOR as of Q1 2022.

  • David Shaw reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • David Shaw sold 1,053 Biora Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $550K.
  • David Shaw first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • David Shaw's Biora Therapeutics, Inc. Common Stock position peaked at $864K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.